Clinical Trial Update: Prevalence-based Health and Economic Model of the Bivalent Versus the Quadrivalent Human Papillomavirus (HPV) Vaccine

View source ↗

Summary

A completed study presenting a prevalence-based health and economic model comparing the bivalent and quadrivalent HPV vaccines.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• Cervarix (human papillomavirus vaccine, bivalent)
• Gardasil (human papillomavirus vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Human Papillomavirus Infection | Status: COMPLETED